Scandion Oncology Correlations
The correlation of Scandion Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Scandion |
The ability to find closely correlated positions to Scandion Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Scandion Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Scandion Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Scandion Oncology AS to buy it.
Related Correlations Analysis
| 0.44 | -0.01 | -0.31 | 0.67 | EXPRS2 | ||
| 0.44 | 0.12 | 0.1 | 0.51 | HNSA | ||
| -0.01 | 0.12 | 0.45 | -0.15 | FLUO | ||
| -0.31 | 0.1 | 0.45 | -0.32 | SANION | ||
| 0.67 | 0.51 | -0.15 | -0.32 | ONCO | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Scandion Stock performing well and Scandion Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Scandion Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EXPRS2 | 4.47 | (0.49) | 0.00 | 0.86 | 0.00 | 13.92 | 41.41 | |||
| HNSA | 2.84 | (0.29) | 0.00 | 1.76 | 0.00 | 8.00 | 26.16 | |||
| FLUO | 3.45 | 0.58 | 0.18 | (1.25) | 2.82 | 8.13 | 31.30 | |||
| SANION | 6.46 | 1.33 | 0.16 | 0.42 | 7.03 | 10.73 | 99.44 | |||
| ONCO | 2.26 | (0.62) | 0.00 | (3.10) | 0.00 | 3.38 | 26.90 |
Scandion Oncology Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scandion Oncology stock to make a market-neutral strategy. Peer analysis of Scandion Oncology could also be used in its relative valuation, which is a method of valuing Scandion Oncology by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Scandion Oncology Corporate Management
Elected by the shareholders, the Scandion Oncology's board of directors comprises two types of representatives: Scandion Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandion. The board's role is to monitor Scandion Oncology's management team and ensure that shareholders' interests are well served. Scandion Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandion Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annie Rasmussen | Chief Director | Profile | |
| Morten Nissen | G Counsel | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Nils MD | Scientific CoFounder | Profile | |
| Johnny MS | CFO CEO | Profile | |
| Alfredo MD | Chief Officer | Profile |